Globus Medical, Inc. with ticker code (GMED) now have 11 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 77 and 58 and has a mean target at $66.36. Now with the previous closing price of $53.02 this would imply there is now a potential upside of 25.2%. There is a 50 day moving average of $53.20 while the 200 day moving average is $58.98. The company has a market cap of 7.44B. The stock price is currently at: 53.2 USD
The potential market cap would be $9,307,291,877 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 26.73, revenue per share of 10.96 and a 7.51% return on assets.
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.
